Inhibitors of the human immunodeficiency virus (HIV) protease are a promising class of antiviral agents that dramatically reduce HIV replication both in culture and in infected patients. However, as for many other antiviral compounds, long-term efficacy of these agents is impeded by the emergence of virus variants with increased resistance to their inhibitory action, following selection of specific mutations in the protease coding sequence. We have studied HIV-1 variants that emerged at different stages of selection in the presence of the C2-symmetrical protease inhibitor ABT-77003. The selection of variants was a gradual process during which mutations accumulated at different sites in the protease, generating virus populations with increasing levels of resistance to the drug. The initially selected viruses had a low level of resistance as well as a markedly reduced replicative capacity. Further accumulation of mutations at secondary sites led to an improvement in both drug resistance and replication. In spite of their reduced infectivity, partially selected virus populations did not readily revert to wild-type when serially passaged in drug-free conditions. Instead, even in the absence of drug, secondary mutations identical to those selected in the presence of the inhibitor continued to emerge. These mutations improved both the intrinsic replicative capacity of the virus and its level of resistance to the inhibitor, suggesting that once committed to drug resistance, readaptation of the enzyme to its natural substrate leads to a reduction of its sensitivity to the inhibitor.
Introduction
Most antiviral drugs that are active against human immunodeficiency virus type 1 (HIV-1) are targeted to enzymatically active proteins that are essential for virus infectivity. Among them, a variety of inhibitors of the virus protease have been shown to possess remarkable antiviral activity and several are currently under evaluation in clinical trials involving HIV-infected patients (Debouck, 1992; Ho et al., 1995; Kageyama et al., 1992; Kempf et al., 1991; Kort et al., 1993; Lam et al., 1994; Roberts et al., 1990; Vacca et al., 1994) . The infectivity of retrovirus particles requires the cleavage of precursor polyproteins into several structural and enzymatically active mature proteins (Hunter, 1994) . This cleavage cascade, referred to as maturation of the particle, is mediated by the virally encoded protease (Kohl et al., 1988; Krausslich & Wimmer, 1988) . In HIV-1, the * Author for correspondence. Fax + 33 1 45 68 88 85. e-mail fclavel@pasteur.fr ~ Present address: Unit~ de Virologic Molrculaire (CNRS URA 1966), Institut Pasteur, Paris, France.
protease is encoded by the 5'-terminal region of the pol open reading frame (Wain-Hobson et al., 1985) . The enzyme has the characteristics of an aspartic protease and was found to be active as a symmetrically assembled dimer (Miller et al., 1989; Navia et at., 1989; Pearl & Taylor, 1987) .
In spite of the antiviral potency of many recently developed HIV-1 protease inhibitors, the emergence of virus variants with decreased sensitivity to these compounds has been described both in cell culture and in treated patients (Condra et al., 1995; Danziani et al., 1993; el-Farrash et al., 1994; Ho et al., 1994; Kaplan et al., 1994; Markowitz et al., 1995; Otto et al., 1993; Patick et al., 1995) . Virus variants that arise from selection by protease inhibitors carry several distinct mutations in the protease coding sequence that appear to emerge sequentially. For most inhibitors studied, a number of these mutations cluster near the active site of the enzyme while others are found at distant sites, suggesting conformational adaptation to primary changes in the active site. In this respect, it has been reported that certain mutations that substantially increase resistance to protease inhibitors can also decrease protease activity and virus replication, as evident when
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A. Borman, S. Paulous and F. Clavel propagated in absence of the inhibitor (Ho et al., 1994; Kaplan et al., 1994) . In these cases, some of the secondary mutations were apparently able to improve mutant infectivity in cell culture. However, evidence for the participation of secondary mutations in the resistance process is not well established. Because many resistance mutations may result in changes in virus infectivity, it is important to determine how the virus adapts to these mutations and how it behaves when further propagated in the absence of the antiviral compound. Additionally, precise evaluation of the genetic stability of selected drug-resistant variants is of clear importance, since the widespread use of antivirals may lead to cases of de novo infections with stably resistant virus strains.
We have examined the pattern of emergence and the potential for reversion of mutations conferring increased resistance of HIV-1 to ABT-77003, a C2-symmetrical protease inhibitor. We report that virus variants obtained after different stages of selection in the presence of increasing doses of ABT-77003 exhibit increasing levels of resistance to the drug as well as differences in replicative capacity in the absence of the drug. In particular, mutations that arise early in the selection process appear to significantly reduce the replicative capacity of the virus when grown in absence of drug. In spite of their selective disadvantage, we found that these early resistance mutations did not revert after serial passages of fully or partially resistant virus in drug-free conditions. Instead, independently of whether the virus is grown with or without the drug, additional mutations emerged which appear to improve both virus infectivity and drug resistance.
Methods

Selection of HIV-1 variants with increased resistance to ABT-77003.
The virus strain used in the selection experiments was HIV-1LA~, derived from molecular clone pBRU3 (Charneau et al., 1992) . Initial virus stocks were produced by transfection of HeLa cells and virus was subsequently passaged in MT4 cells (Harada et al., 1985) . For the selection of variants with increased resistance to ABT-77003, cell-free supernatants from acutely infected MT4 cells containing high levels of HIV-1 p24, as measured by the Dupont HIV p24 core profile ELISA, were used to infect MT4 cells in RPMI medium containing 10 % fetal calf serum, antibiotics and 0.33 gM-ABT-77003 (Abbott). The infectious dose, based on the HIV p24 content of the infecting supernatant, was 100 ng of HIV-1 p24 for 5 x 10 ~ MT4 cells in a final volume of 10 ml. Virus harvested at the peak of particle production of this first infection was labelled pl for passage 1. Subsequent passages of the resulting virus were performed in the same conditions except for the concentration of ABT-77003, which was gradually increased. The concentration of the drug was 0.33 gM for passages 1 and 2 (pl and p2); 0.66 gM for p3 and p4; 1 gM for p5 and p6; and 5 ~M for p7 and p8.
For the evaluation of the reversion potential of the selected variants, p5 and p8 viruses were further propagated in MT4 cells in the absence of the inhibitor. Each virus was passaged at least six times in drug-free conditions. The supernatants thus obtained were labelled 5R1 to 5R6 for the drug-free passages of the p5 virus, and 8R1 to 8R6 for the drugfree passages of p8 virus. In an attempt to increase selective pressure, 5R6 virus was passaged a further six times in drug-free conditions in CEMx174 cells, generating 5R12 supernatant.
Evaluation of'the replicative capacity of the selected virus populations.
The replicative capacity of the viruses obtained after the different passages was evaluated on CEMx 174 cells. Infection of 5 x 105 cells was initiated with the equivalent of 10 ng of HIV-I p24 in a final volume of 1 ml, in 24-well plates. Virus production in the infected cultures was evaluated twice or three times a week by p24 ELISA.
Testing of virus sensitivity to ABT-77003. The sensitivity of the different virus populations obtained either directly after selection in the presence of ABT-77003 or after further passages in drug-free conditions was examined on MT4 cells. The sensitivity to the inhibitor was expressed as a percentage inhibition. This was calculated as follows: multiple cultures of 5 x 105 MT4 cells in a final volume of 1 ml were inoculated with 10 ng HIV-1 p24 of each virus stock and were grown in the absence or presence of increasing concentrations of ABT-77003. After 7 days in culture, the amount of HIV p24 in the supernatants was measured for the treated and untreated cultures. The percentage inhibition corresponds to the fraction of HIV-1 p24 measured in the inhibitor-treated cultures, relative to that measured in the control infection by the same virus stock in the absence of inhibitor.
Sequencing of the protease-coding region of the selected virus populations. Total DNA was isolated from infected cells at the peak of virus production, at the time of virus harvest. Therefore, DNA obtained in cells infected with p7 virus was labelled p8 DNA. Cells were lysed in 10 mM-Tris HC1 pH 7-5, 10 mM-EDTA and 0.6% SDS and incubated for 2 h in the presence of 200 gg/ml proteinase K at 50 °C. After phenol-chloroform extraction and ethanol precipitation, the region coding for the protease was PCR-amplified using the following primers:
The reaction conditions were 50 mM-KC1, 10 mM-Tris-HC1 pH 8.9, I'5mM-MgCI2, 0.1mg/ml gelatin, 0.2mM-dNTPs and 1 U Taq polymerase (Amersham). PCR was carried out for 43 cycles at 92 °C for 10 s, 50 °C for 1 min and 72 °C for 40 s. The products of PCR amplification were digested with Ball and SphI, filled with the Klenow fragment of DNA polymerase I to generate blunt 5' phosphorylated ends, and were ligated to dephosphorylated, SmaI-digested M 13 mp 18, prior to introduction into competent Escherichia eoli DH5c~ cells.
Single-stranded DNA from the resulting plaques was amplified and purified using standard methods and sequenced with the Sequenase kit (USB).
Results
Selection of HIV-1 variants with increased resistance to ABT-77003
To evaluate the impact of mutations conferring resistance to an inhibitor of HIV-1 protease on both drug resistance and drug-free virus replication, and to examine the genetic stability of the resulting virus populations, we selected HIV-1 variants with reduced sensitivity to ABT-77003, a prototypic C2-symmetry-based inhibitor ( infection in MT4 cells. The effects of the drug were expressed as the percentage inhibition of virus production on day 7 of culture compared to a drug-free culture. This method is not meant to calculate the IDs0 or IDg0 of the drug in the described culture conditions, but allows a quick means of assessing the differences in sensitivity to ABT-77003 of the different virus populations analysed here. It should be noted that very little variation was observed between the results of replicate assays using this method, and that the differences in virus growth observed on day 7 reflected very well the global differences observed in kinetics experiments in which p24 was measured throughout the infection at 48 h intervals (data not shown).
As previously reported, serial passage of HIV-1 in the presence of increasing concentrations of ABT-77003 resulted in the selection of variants with increased resistance to the drug (Kaplan et al., 1994) . A similar, gradual emergence of resistance was witnessed here, as sensitivity to ABT-77003 decreased with the number of passages in the presence of the drug (Fig. 1) . Virus p5, which had been produced in the presence of 1 gM of the inhibitor, exhibited a level of resistance that only slightly differed from that of wild-type virus. Conversely, the replication of p7 virus was only partially inhibited by 5 pM-ABT-77003 and p8 virus was totally resistant to this concentration of drug. Although only the results of p5, p7 and p8 viruses are shown, it should be noted that all the virus stocks passing from p2 to p8 showed a gradually more pronounced reduction in sensitivity to the inhibitor (data not shown).
To determine the mutations that reduced sensitivity of passaged virus to ABT-77003, sequences of clones of PCR-amplified DNA from cells infected with virus from the different passages were determined. This analysis revealed a gradual accumulation of mutations in the protease-coding region (Fig. 2) . Many of the mutations found have been described previously in similar studies using protease inhibitors. The first mutation that accumulated significantly was a single substitution of valine to isoleucine at position 32 (V32I). This mutation was first detected as a minor population in p3 and p4 virus mixtures, but was found in all clones of p5 virus. Later in the selection process, other amino acid substitutions arose at positions 46 (M46I), 82 (V82A) and 71 (A71V). All DNA clones of p8 virus, grown in the presence of 5 laM-ABT-77003, contained both mutations V32I and M46I, five out of six clones carried mutation V82A and one clone had mutation A71V in combination with the three others. Along the selection process, a variety of other single or double amino acid substitutions were found in single clones but were not selected for during subsequent passages and thus did not seem to be central to the drug resistance process. These 'nonrepresentative' clones are most likely the results of the high error rate of Taq polymerase (or of the HIV RT enzyme itself). Apart from one clone representing a heavily G --, A hypermutated genome (data not shown), we did not detect any obviously defective or truncated protease sequences.
Drug-free replication of ABT-77OO3-resistant virus populations
Since the mutations that arose following ABT-77003 selection affected highly conserved amino acid residues of the protease, we wished to evaluate the impact of their emergence on the replicative capacity of the selected virus populations in drug-free conditions. The kinetics of productive infection by p2, p5 and p8 viruses were evaluated in CEMx174 cells after inoculation with identical quantities of virus, based on the amounts of HIV-1 p24 measured by ELISA. Virus p2, whose protease sequence did not contain any of the four mutations described above, did not differ substantially from wild-type virus in its replicative capacity. Conversely, as shown in Fig. 3 compared to wild-type. Since mutation V32I was found in all clones of p5 virus, we conclude that this mutation, which resulted in moderate resistance to ABT-77003, also impaired virus replication in absence of the drug. A delay in virus production was also noticeable with p8 virus, but this delay was smaller than that seen with p5 virus. Therefore, the mutations that accumulated between passage 5 and passage 8 appeared to partially correct the replicative defect found in p5 virus. In fact, it appeared that these additional mutations had a double impact on the phenotype of the corresponding viruses: improving drug-free replication and enhancing drug resistance.
Potential for reversion of resistance mutations in drugfree conditions
Some of the initially selected resistance mutations, particularly mutation V32I, appeared to impair HIV-1 replication in the absence of ABT-77003. We thus tested whether serial passages of resistant viruses in these conditions would lead to rapid selection of viruses in which reversion of some of the mutations had occurred. Therefore, both p5 and p8 viruses were serially passaged in drug-free medium. Viruses obtained after two, four, six and 12 such passages of p5 virus were labelled 5R2 to 5R12, and p8 virus was passaged two, four or six times in drug-free medium to produce 8R2, 8R4 and 8R6 virus populations. These populations were sequenced in the protease-coding region and analysed for their replicative capacities in drug-free conditions or in the presence of different concentrations of ABT-77003. During serial drug-free passage of p8 virus, in which both V32I and M46I mutations were found in all sequenced clones, we observed the gradual addition of A71V and of V82A, mutations that were poorly represented in clones of the parental p8 virus. After four or six passages in drug-free conditions, all sequenced clones were found to contain all four mutations, indicating that viruses with the four combined mutations have a selective growth advantage in the absence of ABT-77003 (Fig. 4, 8R4 and 8R6) . ABT-77003 sensitivity of 8R2 and 8R4 viruses was evaluated using the assay described earlier. No significant differences in ABT-77003 sensitivity were detected between p8, 8R2 and 8R4 viruses: all three viruses were equally resistant to concentrations of the drug up to 5 gN (Fig. 5a ). In addition, examination of the drug-free replicative capacity of 8R2 and 8R4 viruses in CEMx 174 cells did not reveal any significant difference in the kinetics of replication of these viruses compared to p8 virus (data not shown). In spite of this apparent lack of differences, the selection for virus genomes carrying all four mutations must reflect a selective advantage. Indeed, competition between virus populations in a concurrent
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replication system is a much more sensitive means of detecting differences in replicative capacities than is the separate evaluation of replication kinetics (Coffin, 1995) .
Since the replicative capacity of p5 virus was the lowest on the basis of CEMx174 cell infection kinetics, we expected to observe that serial passages of this virus in drug-free conditions would lead to the rapid selection of clones exhibiting reversion of the V32I mutation, the only mutation initially found in all sequenced p5 protease regions. However, drug-free propagation of p5 virus did not lead to quick reversion of the V32I mutation. Instead, in 5R2 virus, two clones out of five were found to carry the M46I mutation in combination with V32I, and one clone was found with the A71V mutation. This latter mutation was not dramatically selected during continued drug-free virus replication (see 5R4 and 5R6, Fig. 4 ). In the 5R4 and 5R6 populations, more than half of the sequenced clones (nine out of 15) contained both V32I and M46V mutations and five of 11 clones sequenced from the 5R12 virus population also possessed both the V32I and M46V changes. Interestingly, in the 5R12 population, which had been produced by repeated drug-free passages in CEMx174 cells, six of the 11 sequenced clones possessed the A71V change, although this mutation was rarely seen in conjunction with V32I and M46V. Although the growth kinetics of the 5R viruses in CEMx 174 cells did not differ significantly from that of p5 virus (data not shown), these viruses exhibited a slight but reproducible decrease in their sensitivity to ABT-77003 (Fig. 5 b) . The observed gradual selection for virus genomes containing the M46I mutation in addition to V32I is a strong indication that M46I can improve the impaired virus replicative capacity induced by the V32I mutation. Since the resulting virus population displayed slightly increased resistance to ABT-77003, these results again suggest that in viruses partially selected for drug resistance, addition of secondary mutations in the protease can improve both drug-free replication and drug resistance.
Discussion
To date, several studies have examined the acquisition of HIV-1 resistance to protease inhibitors and have determined the changes required in the protease to reduce sensitivity to a variety of these compounds (Condra et al., 1995; Danziani et al., 1993; el-Farrash et al., 1994; Ho et al., 1994; Kaplan et al., 1994; Markowitz et al., 1995; Otto et al., 1993 ; Patick et al., 1995 ; Sardana et al., 1994) . In vivo and in vitro, HIV-1 resistance to several distinct protease inhibitors is often induced by common amino acid substitutions that can confer various levels of cross-resistance (Condra et al., 1995) . The corresponding amino acids are generally well conserved within HIV-1 isolates (Myers et al., 1994) , a sign of their importance for protease function. Directed mutagenesis of some of these residues can lead to a critical loss of protease activity (Loeb et al., 1989) . Accordingly, it has been described that some mutations emerging during selection for HIV-1 resistance to protease inhibitors can impair virus infectivity to various degrees, this loss in infectivity being in turn partially corrected by the occurrence of substitutions at secondary sites (Ho et al., 1994; Kaplan et al., 1994) .
Because resistance mutations can impair HIV-1 replicative capacity, we wished to examine the genetic stability of viruses selected for resistance to protease inhibitors. During the initial selection for resistance to ABT-77003 (Kageyama et al., 1992; Kempf et al., 1991 Kempf et al., , 1993 Kort et al., 1993) , viruses gradually and sequentially accumulated up to a total of four specific changes in the protease. These four changes were previously noted for viruses with reduced sensitivity to a number of different HIV-1 protease inhibitors (Condra et al., 1995; Kaplan et al., 1994; Otto et al., 1993; Patick et al., 1995) . While the wild-type virus was not passaged in parallel in the absence of the inhibitor as a control, we feel it is extremely unlikely that such mutations resulted from tissue culture adaptation. Firstly, to our knowledge, such adaptational mutations have never been reported for the protease gene by others. Secondly, the parental HIV-1LA~ virus has been used extensively by us for many different studies on virus processing and maturation and thus stocks of this virus have been passaged multiple times through several different T cell lines. In such multiply passaged virus populations, we have never observed conserved mutations in the protease gene or in the regions corresponding to proteolytic cleavage sites.
In the present study, the first mutation to occur (V32I) resulted in a virus (p5) which was moderately less sensitive to ABT-77003, but which was substantially impeded in its replicative capacity. When virus carrying the V32I change was passaged further in the presence of drug, a second mutation (M46I) accumulated, with or without additional A71V or V82A changes. This virus population (p8) was globally less sensitive to the drug than the p5 population and demonstrated partially rescued infectivity. Interestingly, the M46I change was also shown to partially rescue the replication of resistant virus carrying a primary R8Q mutation, found to severely impair virus replication (Ho et al., 1994) .
The principal finding of our study is that in partially selected virus populations, the selection pressure for the emergence of mutations which increase virus fitness can persist after removal of the drug. This effect was observed at two different stages of the selection process. In p5 virus, which carried only mutation V32I and whose replicative capacity was clearly decreased compared to wild-type virus, the addition of mutation M46I was progressively selected for in serial drug-free passages. A similar situation was observed in experiments using p8 viruses, which all carried the double V32I/M46I mutations, with or without additional V82A and A71V mutations. These virus populations, when cultured in the absence of the drug, were found to accumulate V82A and particularly the A71V mutation. Although we did not detect an increase in drug resistance in virus populations only partially mutated at positions 82 and 7 l, and those that carried all four mutations, it is known that mutation V82A can by itself increase drug resistance, and even more so in the context of V32I (Kaplan et al., 1994) . Overall, these results underline the high flexibility of the HIV-1 protease in counteracting the activity of inhibitors and in readapting to its natural substrate while retaining a resistant phenotype.
There are two possible explanations for the fact that the p5 virus population underwent second site mutation rather than direct reversion of the original mutation in the absence of drug-induced selective pressure. It is possible that even the relatively low ABT-77003 doses used to select p5 virus were sufficient to eliminate all residual wild-type V32 genomes and to select a low, undetectable number of genomes bearing both V32I and M46I. If this is the case, outgrowth of the doubly mutated virus might be more rapid than reversion to wild-type sequence. Additionally, such a situation is not likely to be found in vivo, where possible silent wild-type genomes could emerge once the drug pressure is removed. However, given the extremely high mutation rate of HIV and the fact that a revertant at position 32 would appear to have a strong selective advantage over the V32I-M46I double mutant (see for example Fig. 3 ), we feel that this explanation is not very likely. Alternatively, it is possible that the V32I virus is forced into forward mutation rather than reversion due to the presence of mutations elsewhere in the genome. Indeed, mutations at the cleavage sites between NCp7 and p6 Gag domains were recently reported in viruses that had acquired resistance to a protease inhibitor (Doyon et al., 1995; Lamarre, 1995) . However, sequencing of the cleavage sites in gag for the p5R4 and p8R4 virus populations revealed no differences from the wild-type sequence. Studies using molecularly cloned viruses with each of the combinations of mutations will be required to further address these issues.
Finally, the reduction in replicative capacity of HIV-1 populations that are fully or partially resistant to an antiretroviral could have several important implications for the treatment of HIV-infected patients. First, a transient or permanent impairment of virus replication may be beneficial by itself, so that the maintenance of a selective pressure for mutations that impair virus infectivity could prove useful even after emergence of a resistant phenotype. Second, the impact of resistance mutations on virus replication will certainly influence the spread of resistant virus to newly infected subjects, a problem recently described with AZT-resistant strains (Conlon et al., 1994; Masquelier et al., 1995; Najera et al., 1995) . The observations reported here concerning the frequency of reversion of drug resistance mutations could indicate that in spite of a slight reduction in infectivity, fully resistant virus strains could persist in an individual after withdrawal of an antiviral or after transmission to a new host, before any antiviral treatment is instituted.
